Research Topics
Species | Dirk HoseSummaryAffiliation: University of Heidelberg Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myelomaDirk Hose
Medizinische Klinik V, Universitatsklinikum Heidelberg, Im Neuenheimer Feld, Heidelberg, Germany
Haematologica 96:87-95. 2011..Proliferation of malignant plasma cells is a strong adverse prognostic factor in multiple myeloma and simultaneously targetable by available (e.g. tubulin polymerase inhibitors) and upcoming (e.g. aurora kinase inhibitors) compounds...- Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaDirk Hose
Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
Blood 113:4331-40. 2009..Using gene expression profiling, aurora kinase inhibitors as a promising therapeutic option in myeloma can be tailoredly given to patients expressing aurora-A, who in turn have an adverse prognosis... 
The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratificationDirk Hose
Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
Srp Arh Celok Lek 139:84-9. 2011..Thus, assessment of B2M and ISS-stage, iFISH, and GEP is considered extended routine diagnostics in therapy requiring multiple myeloma patients for risk assessment and, even now, to a certain extent selection of treatment...- Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarraysKarene Mahtouk
INSERM, U847, Montpellier, F 34197 France
BMC Cancer 10:198. 2010..In the past few years, many myeloma growth factors (MGF) have been described in the literature. However, their relative importance and the nature of the cells producing MGF remain unidentified for many of them... 
Induction of angiogenesis by normal and malignant plasma cellsDirk Hose
Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
Blood 114:128-43. 2009..Aberrant expression of proangiogenic and down-regulation of antiangiogenic genes by MMCs further increases the angiogenic stimulus, together leading to bone marrow angiogenesis at various degrees in all myeloma patients...- Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24Olaf Christensen
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
J Immunother 32:613-21. 2009..The current data demonstrate that Melan-A analog specific T-cells crossreact with HM1.24(aa22-30). They might be a tool for the future use in immunotherapy against MM... - Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routineTobias Meissner
Medizinische Klinik V, Universitatsklinikum Heidelberg, Germany
Clin Cancer Res 17:7240-7. 2011.... - Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myelomaJens Hillengass
Department of Hematology, Oncology, and Rheumatology, University of Heidelberg, Heidelberg, Germany
Int J Cancer 122:2871-5. 2008..Our findings will have important implications for the design, analysis and stratification for clinical studies of patients with MM in particular if compounds with antiangiogenic activity are used... - Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasoneUlrike Klein
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
Cancer 117:2136-44. 2011..In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM)... - Timing of the high-dose therapy in the area of new drugsStefan Schmitt
Department of Medicine V, University of Heidelberg, Heidelberg, Germany
Srp Arh Celok Lek 139:90-4. 2011..These results offer new perspectives in the treatment of MM with a reasonable hope of cure... - Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)Tilmann Bochtler
Amyloidosis Center, Department of Internal Medicine, Division of Hematology Oncology Rheumatology, University of Heidelberg, Heidelberg, Germany
Blood 117:3809-15. 2011.... - Clinical and prognostic role of annexin A2 in multiple myelomaAnja Seckinger
Medizinische Klinik V, Universitatsklinikum Heidelberg, Heidelberg, Germany
Blood 120:1087-94. 2012..ANXA2 exemplifies an interesting class of targetable bone-remodeling factors expressed by normal and malignant plasma cells and the BM microenvironment that have a significant impact on survival of myeloma patients... - Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17pKai Neben
Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, Heidelberg, Germany
Blood 119:940-8. 2012..In conclusion, the adverse impact of del(17p13) on PFS and OS could be significantly reduced by bortezomib-based treatment, suggesting that long-term administration of bortezomib should be recommended for patients carrying del(17p13)... - Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculationJens Hillengass
German Cancer Research Center, Department of Radiology University of Heidelberg, Department of Hematology, Oncology and Rheumatology, Heidelberg, Germany
Clin Cancer Res 15:3118-25. 2009.... - NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasmNiels Weinhold
Medizinische Klinik V, Universitaetsklinikum Heidelberg, Heidelberg, Germany
Genes Chromosomes Cancer 49:333-41. 2010..Our results indicate that the gain of chromosome 5 might play an important role in the pathogenesis of HD... - Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myelomaIsabelle Herth
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
Exp Hematol 41:231-40. 2013..In conclusion, Thalidomide maintenance therapy has profound implications on T cell pattern and activation status, which compromise antigen specific antitumor immunity... - Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myelomaJens Hillengass
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
Haematologica 97:1757-60. 2012..We suggest that residual disease after high-dose chemotherapy detected by magnetic resonance imaging increases the risk of relapse. Therefore, myeloma patients with such findings after treatment might benefit from further cytoreduction... - Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantationKai Neben
Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
Haematologica 95:1150-7. 2010..Specific changes in interphase cells can be detected by fluorescent in situ hybridization, which overcomes the problem of the lack of dividing cells required for conventional cytogenetics... - Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instabilityTilmann Bochtler
Department of Internal Medicine, Division of Hematology Oncology, Amyloidosis Clinic, University of Heidelberg, Heidelberg, Germany
Blood 111:4700-5. 2008..001) in both groups. Similar branching patterns were observed in an oncogenetic tree model, indicating a common mechanism of underlying karyotypic instability in these plasma cell disorders... - Modeling risk stratification in human cancerThierry Reme
INSERM UM1, U1040, Institut de Recherche en Biothérapie, 34295 Montpellier, France, Medizinische Klinik V, Universitatsklinikum Heidelberg, Nationales Centrum fur Tumorerkrankungen, 69120 Heidelberg, Germany and INSERM, U896, Institut de Recherche en Cancérologie de Montpellier, 34295 Montpellier, France
Bioinformatics 29:1149-57. 2013.... - Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myelomaSebastian Belle
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
Eur J Haematol 81:26-35. 2008..The aim of this study is the identification of HLA-A2 restricted T-cell epitopes in the conserved region of the immunoglobulin-G-heavy-chain (IgGH) that can be used for immunotherapy in multiple myeloma (MM) patients...